Add‐On Telitacicept Significantly Improves Outcome of Patients With Refractory Ocular Myasthenia Gravis a Real‐World Case Series
Our preliminary findings indicate that telitacicept represents a promising and well-tolerated adjunct therapy for refractory ocular symptoms in MG, providing significant clinical evidence to support this novel therapeutic approach.
Authors
- Zhijun Li (ORCID: https://orcid.org/0009-0009-4250-3427)
- Bitao Bu (ORCID: https://orcid.org/0000-0001-5369-7751)
- Mengcui Gui
- Yue Li
- Jing Lin
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Brain and Behavior
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1002/brb3.71157
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- Health Commission of Hubei Province
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province